Women with long QT syndrome should be coun- seled about maternal and fetal risks prior to CLINICAL STATEMENTS AND GUIDELINES pregnancy to ensure ongoing beta-blocker ther- apy. The risk of SCA or SCD is significantly higher during the 9 months after delivery, most notably among women with LQT2.S10.2-1,S10.2-6,S10.2-7 A large retrospective analysis from the long QT syndrome registry demonstrated an odds ratio of 40.8 for syncope, SCA, or SCD among women with long QT syndrome in the 9 months postpartum; treatment with beta blockers during pregnancy was independently associated with decreased Overall arrhythmic events during preg- nancy are not increased among women receiving In a case- control study, women with LQT1 who did not receive beta blockers during pregnancy, particu- larly those with prior syncope, were at significantly increased risk of SCA or syncope.S10.2-8 Frequency of events returned to prepregnancy levels after Maternal use of beta blockers during pregnancy is associated with decreased newborn birth weight and hypoglycemia,S10.2-9 but it is not associated with increased risk of Fetal bradycardia is asso- ciated with fetal long QT syndrome and should not independently provoke discontinuation of ; these infants are at increased risk of death and require care- ful neonatal monitoring and treatment.S10.2-13 As 50% of offspring may be affected with long QT syndrome, with highest risk of adverse events in infancy and childhood, screening of the newborn at birth and during infancy for long QT syndrome 2. Available data on electrical fields associated with properly applied AED patches suggest that the fetus is safe; no observational data are available to the contrary. Anterolateral defibrillator pad placement is preferred with the lateral pad/pad- dle placed under the breast tissue, which is an important consideration in the pregnant patient. 3. 